Follow
inyoung jung
inyoung jung
Verified email at pennmedicine.upenn.edu
Title
Cited by
Cited by
Year
CRISPR-engineered T cells in patients with refractory cancer
EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen, KL Weber, E Lancaster, ...
Science 367 (6481), eaba7365, 2020
11422020
Directed evolution of CRISPR-Cas9 to increase its specificity
JK Lee, E Jeong, J Lee, M Jung, E Shin, Y Kim, K Lee, I Jung, D Kim, ...
Nature communications 9 (1), 3048, 2018
4752018
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ...
Nature medicine 28 (4), 724-734, 2022
2232022
CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells
IY Jung, YY Kim, HS Yu, M Lee, S Kim, J Lee
Cancer research 78 (16), 4692-4703, 2018
1672018
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
W Kong, A Dimitri, W Wang, IY Jung, CJ Ott, M Fasolino, Y Wang, ...
The Journal of clinical investigation 131 (16), 1-16, 2021
542021
Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies
IY Jung, J Lee
Molecules and cells 41 (8), 717-723, 2018
542018
Simultaneous conversion of glucose and xylose to 3-hydroxypropionic acid in engineered Escherichia coli by modulation of sugar transport and glycerol synthesis
IY Jung, JW Lee, WK Min, YC Park, JH Seo
Bioresource technology 198, 709-716, 2015
502015
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
IY Jung, V Narayan, S McDonald, AJ Rech, R Bartoszek, G Hong, ...
Science translational medicine 14 (670), eabn7336, 2022
332022
Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors
IY Jung, E Noguera-Ortega, R Bartoszek, SM Collins, E Williams, M Davis, ...
Cell Reports Medicine 4 (6), 2023
132023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
IY Jung, RL Bartoszek, AJ Rech, SM Collins, SK Ooi, EF Williams, ...
Cancer discovery 13 (7), 1636-1655, 2023
72023
Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer
S Lundh, IY Jung, A Dimitri, A Vora, JJ Melenhorst, JK Jadlowsky, ...
Clinical and Experimental Medicine 20, 469-480, 2020
72020
Manipulated Immunoregulatory Element And Immunity Altered Thereby
SJ Kim, YY Kim, YU Ho-Sung, I Jung, JM Lee
US Patent App. 16/324,955, 2019
72019
Enhanced costimulatory signaling improves CAR T-cell effector responses in CLL
MKA Collins, IY Jung, Z Zhao, K Apodaca, W Kong, S Lundh, JA Fraietta, ...
Cancer research communications 2 (9), 1089-1103, 2022
52022
A failure to start: aborted activation of CAR T cells in chronic lymphocytic leukemia
MK Collins, W Kong, I Jung, M Wang, SM Lundh, CH June, JJ Melenhorst
Blood 134, 681, 2019
22019
FOXO1 is a master regulator of memory programming in CAR T cells
AE Doan, KP Mueller, AY Chen, GT Rouin, Y Chen, B Daniel, J Lattin, ...
Nature, 1-8, 2024
12024
FOXO1 is a master regulator of CAR T memory programming
A Doan, KP Mueller, A Chen, GT Rouin, B Daniel, J Lattin, Y Chen, ...
Research Square, 2023
12023
FOXO1 is a master regulator of CAR T memory programming
C Mackall, A Doan, K Mueller, A Chen, G Rouin, B Daniel, J Lattin, ...
12023
247 FOXO1 is a master regulator of CAR T memory programming
AE Doan, KP Mueller, A Chen, G Rouin, B Daniel, J Lattin, Y Chen, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
12023
B-CLL mediated resistance to CAR T cell therapy via insufficient activation is CAR-independent
MK Collins, W Kong, I Jung, SM Lundh, JJ Melenhorst
Blood 136, 44, 2020
12020
Publisher Correction: FOXO1 is a master regulator of memory programming in CAR T cells
AE Doan, KP Mueller, AY Chen, GT Rouin, Y Chen, B Daniel, J Lattin, ...
Nature, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20